Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
Strong. Novartis AG scores higher than 87% of the 2,231 companies Ryufin scores.
Carried by valuation and capital allocation, held back by cycle position.
Healthcare median 19 · all companies 55
26% of the score
Novartis AG is valued at 16.7x its operating profit before acquisition amortisation (EBITA), including debt: an ordinary multiple.
18% of the score
Over 7 years the business earned 13% a year after tax on the capital it uses.
16% of the score
For every dollar of operating profit earned over 6 years, yearly profit grew by 10 cents. It did so while using less capital than before.
14% of the score
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
12% of the score
Today's operating margin of 32% is 1.50x its normal 22%: near a peak, where margins tend to fall back. Normal is half the 10 year median, half the last four years, so a margin that has held is not taken for a peak.
8% of the score
What the debt weighs against the profit that has to carry it.
6% of the score
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. Where a criterion cannot be measured from the filings it is taken out and the remaining weights scale up; a company needs 60% of the weight covered, and always a price, to get a score.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2025-06-30, latest annual report FY2025.
Ranks #2 of 7 by RyuScore